What Is Cyclobenzaprine?
Cyclobenzaprine is one of the most commonly prescribed muscle relaxants for acute muscle spasms and musculoskeletal pain. Brand names include Flexeril and Amrix. It's structurally similar to tricyclic antidepressants and is intended for short-term use alongside rest and physical therapy.1
How It Works2
- Acts primarily in the brain stem
- Reduces muscle hyperactivity
- Doesn't directly relax muscles
- May affect alpha motor neurons
- Sedation contributes to effect
Uses
- Acute muscle spasms
- Muscle strains and sprains
- Low back pain with spasm
- Neck pain with spasm
- Usually short-term (2-3 weeks)
Dosing3
Immediate Release
- 5-10 mg three times daily
- Often started at lower dose
- Taken with or without food
Extended Release
- 15-30 mg once daily
- Take at same time each day
Common Side Effects
- Drowsiness (most common)
- Dry mouth
- Dizziness
- Fatigue
- Constipation
- Blurred vision
- Headache
Important Precautions
- Very sedating—affects driving
- Avoid alcohol
- Avoid in elderly (Beers criteria)
- Not for use with MAO inhibitors
- Caution with heart disease
- Can cause urinary retention
- Avoid with glaucoma
Drug Interactions
- Other CNS depressants
- MAO inhibitors (avoid)
- Tramadol (serotonin syndrome risk)
- Other serotonergic drugs
- Anticholinergic drugs
Not for Chronic Use
- Evidence supports short-term use only
- Effectiveness decreases over time
- Not appropriate for chronic pain
- Tolerance may develop
Elderly Concerns
- High anticholinergic burden
- Increased fall risk
- Cognitive effects
- Generally avoided in >65
- If used, lower doses
References
- Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions. J Pain Symptom Manage. 2004;28(2):140-175.
- Share NN, McFarlane CS. Cyclobenzaprine: a novel centrally acting skeletal muscle relaxant. Neuropharmacology. 1975;14(9):675-684.
- Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001;161(13):1613-1620.